Denosumab

ArticlesRefrigerated StorageLactation Safety InformationNew Medicines ·
446457007

Articles

Refrigerated Storage

ProliaAmgen Ltd

Amgen Ltd
Prolia
60 mg solution for injection in a pre-filled syringe

In the event of an inadvertent temperature excursion the following data may be used:
Prolia vials remain stable when exposed to a temporary room temperature exposure up to 30°C. The cumulative room temperature exposure time must not exceed 30 days and exposure should be limited to one to two excursions. In the event of a temporary room temperature exposure, Prolia may be returned to the recommended condition of 2-8°C until the product expiry.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

Contact Amgen Ltd in cases where additional stability data is required. Refer to the current BNF for company contact details.

No
Yes
29 May 2019
London MI Service

XGEVAAmgen Ltd

Amgen Ltd
XGEVA
120 mg solution for injection

In the event of an inadvertent temperature excursion the following data may be used:
Xgeva vials remain stable when exposed to a temporary room temperature exposure up to 30°C. The cumulative room temperature exposure time must not exceed 30 days and exposure should be limited to one to two excursions. In the event of a temporary room temperature exposure, Xgeva may be returned to the recommended condition of 2-8°C until the product expiry.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

Contact Amgen Ltd in cases where additional stability data is required. Refer to the current BNF for company contact details.

No
Yes
29 May 2019
London MI Service

Lactation Safety Information

Bisphosphonate
No published evidence of safety
Due to the drug’s properties, low levels anticipated in milk which are likely to be degraded in infant’s GI tract
Avoid in preterm infants and neonates as large protein molecules may appear in colostrum
17 September 2020

New Medicines

denosumab biosimilar (GP2411)Osteoporosis

Information

denosumab biosimilar (GP2411)
Biosimilar
Sandoz
Sandoz

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Antibody that inhibits RANKL protein, an activator of osteoclasts
In England and Wales more than 2 million women have osteoporosis and there are around 180,000 fractures per year due to osteoporosis [2].
Osteoporosis
Subcutaneous

Trial or other data

Evidence based evaluations

denosumab biosimilar (SB16)Osteoporosis

Information

denosumab biosimilar (SB16)
Biosimilar
Samsung Bioepis
Samsung Bioepis

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Human monoclonal antibody that inhibits RANKL protein, an activator of osteoclasts
1 in 3 women and 1 in 5 men will have an osteoporotic fracture in their lifetime. Yhere are around 180,000 fractures per year due to osteoporosis in England and Wales [2]
Osteoporosis
Subcutaneous

Evidence based evaluations